Ascendis Pharma A/S (NASDAQ:ASND) PT Raised to $289.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target hoisted by equities research analysts at Wells Fargo & Company from $264.00 to $289.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 98.82% from the company’s previous close.

ASND has been the topic of a number of other reports. Bank of America lifted their price objective on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Oppenheimer reaffirmed an “outperform” rating and issued a $190.00 price objective (up from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday. Jefferies Financial Group boosted their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Evercore ISI increased their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Citigroup dropped their price objective on Ascendis Pharma A/S from $193.00 to $178.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $193.77.

Ascendis Pharma A/S Stock Up 4.1 %

Shares of ASND stock traded up $5.79 during mid-day trading on Tuesday, reaching $145.36. 1,161,814 shares of the stock traded hands, compared to its average volume of 431,050. The company has a market cap of $8.46 billion, a price-to-earnings ratio of -15.13 and a beta of 0.63. The stock’s fifty day simple moving average is $132.51 and its two-hundred day simple moving average is $136.47. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently bought and sold shares of ASND. Vestal Point Capital LP bought a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at $78,719,000. Price T Rowe Associates Inc. MD increased its holdings in Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after acquiring an additional 336,976 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after acquiring an additional 229,995 shares during the period. Finally, Westfield Capital Management Co. LP lifted its holdings in Ascendis Pharma A/S by 6.0% during the fourth quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company’s stock valued at $507,658,000 after purchasing an additional 228,457 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.